The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade

Cell Death and Differentiation

Volumn 23, Issue 6, 2016, Pages 1004-1015

  Yamazaki, T ^a,b,c   Pitt, J M ^a,b,c   Vetizou M ^a,b,c   Marabelle, A ^a,b   Flores, C ^a,b,c   Rekdal, O ^d,e   Kroemer, G ^{a,c,f,g,h,i,j,k,l}   Zitvogel, L ^a,b,c,i,l  

^a University Paris XI   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d UNIVERSITY OF TROMSØ   (Norway)

^e LYTIX BIOPHARMA AS   (Norway)

^f CENTRE DE RECHERCHE DES CORDELIERS   (France)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h INSERM   (France)

ⁱ SORBONNE UNIVERSITÉ   (France)

^j HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^k KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^l Center of Clinical Investigations in Biotherapies of Cancer   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; ONCOLYTIC PEPTIDE LTX 315; POLYPEPTIDE ANTIBIOTIC AGENT; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG; ALPHA BETA INTERFERON RECEPTOR; CYTOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HIGH MOBILITY GROUP B1 PROTEIN; IFNAR1 PROTEIN, MOUSE; INTERLEUKIN 2 RECEPTOR BETA; LTX-315; MONOCLONAL ANTIBODY; OLIGOPEPTIDE; PDCD1 PROTEIN, MOUSE; TLR4 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER RESISTANCE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG MECHANISM; DRUG POTENTIATION; IMMUNOMODULATION; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PRECLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; TH1 CELL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ALLOTRANSPLANTATION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOLOGY; DEFICIENCY; DRUG RESISTANCE; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; MORTALITY; NEOPLASM; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CHEMOKINE CXCL10; CTLA-4 ANTIGEN; CYTOKINES; DRUG RESISTANCE, NEOPLASM; HMGB1 PROTEIN; INTERLEUKIN-2 RECEPTOR BETA SUBUNIT; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS; OLIGOPEPTIDES; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTOR, INTERFERON ALPHA-BETA; TOLL-LIKE RECEPTOR 4; TRANSPLANTATION, HOMOLOGOUS;

EID: 84963546143     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2016.35     Document Type: Article

References (44)

1. Marabelle A, Kohrt H, Caux C, Levy R. Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res 2014; 20: 1747-1756
2. Church SE, Galon J. Tumor microenvironment and immunotherapy: the whole picture is better than a glimpse. Immunity 2015; 43: 631-633
3. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12: 298-306
4. Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell RC, Zhou G., et al. Depleting tumorspecific Tregs at a single site eradicates disseminated tumors. J Clin Invest 2013; 123: 2447-2463
5. Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH., et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol 2010; 28: 4324-4332
6. Kim Y, Spitz GS, Veturi U, Lach FP, Auerbach AD, Smogorzewska A. Regulation of multiple DNA repair pathways by the Fanconi anemia protein SLX4. Blood 2013; 121: 54-63
7. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S., et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012; 366: 925-931
8. Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, Srinivasan M., et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 2013; 1: 32-42
9. Harrington KJ, Puzanov I, Hecht JR, Hodi FS, Szabo Z, Murugappan S., et al. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1- derived oncolytic immunotherapy. Exp Rev Anticancer Ther 2015; 15: 1389-1403
10. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002; 415: 389-395
11. Rosenfeld Y, Shai Y. Lipopolysaccharide (endotoxin)-host defense antibacterial peptides interactions: role in bacterial resistance and prevention of sepsis. Biochim Biophys Acta 2006; 1758: 1513-1522
12. Brown KL, Hancock RE. Cationic host defense (antimicrobial) peptides. Curr Opin Immunol 2006; 18: 24-30
13. Wieczorek M, Jenssen H, Kindrachuk J, Scott WR, Elliott M, Hilpert K., et al. Structural studies of a peptide with immune modulating and direct antimicrobial activity. Chem Biol 2010; 17: 970-980
14. Schweizer F. Cationic amphiphilic peptides with cancer-selective toxicity. Eur J Pharmacol 2009; 625: 190-194
15. Hoskin DW, Ramamoorthy A. Studies on anticancer activities of antimicrobial peptides. Biochim Biophys Acta 2008; 1778: 357-375
16. Mader JS, Hoskin DW. Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment. Expert Opin Investig Drugs 2006; 15: 933-946
17. Papo N, Shai Y. Host defense peptides as new weapons in cancer treatment. Cell Mol Life Sci 2005; 62: 784-790
18. Masson PL, Heremans JF. Lactoferrin in milk from different species. Comp Biochem Physiol B 1971; 39: 119-129
19. Yoo YC, Watanabe R, Koike Y, Mitobe M, Shimazaki K, Watanabe S., et al. Apoptosis in human leukemic cells induced by lactoferricin, a bovine milk protein-derived peptide: involvement of reactive oxygen species. Biochem Biophys Res Commun 1997; 237: 624-628
20. Yoo YC, Watanabe S, Watanabe R, Hata K, Shimazaki K, Azuma I. Bovine lactoferrin and lactoferricin, a peptide derived from bovine lactoferrin, inhibit tumor metastasis in mice. Jpn J Cancer Res 1997; 88: 184-190
21. Eliassen LT, Berge G, Sveinbjornsson B, Svendsen JS, Vorland LH, Rekdal O. Evidence for a direct antitumor mechanism of action of bovine lactoferricin. Anticancer Res 2002; 22: 2703-2710
22. Eliassen LT, Berge G, Leknessund A, Wikman M, Lindin I, Lokke C., et al. The antimicrobial peptide, lactoferricin B, is cytotoxic to neuroblastoma cells in vitro and inhibits xenograft growth in vivo. Int J Cancer 2006; 119: 493-500
23. Mader JS, Salsman J, Conrad DM, Hoskin DW. Bovine lactoferricin selectively induces apoptosis in human leukemia and carcinoma cell lines. Mol Cancer Ther 2005; 4: 612-624
24. Mader JS, Richardson A, Salsman J, Top D, De Antueno R, Duncan R., et al. Bovine lactoferricin causes apoptosis in Jurkat T-leukemia cells by sequential permeabilization of the cell membrane and targeting of mitochondria. Exp Cell Res 2007; 313: 2634-2650
25. Haug BE, Camilio KA, Eliassen LT, Stensen W, Svendsen JS, Berg K., et al. Discovery of a 9-mer cationic peptide (LTX-315) as a potential first in class oncolytic peptide. J Med Chem (e-pub ahead of print 16 March 2016
26. Zhou H, Forveille S, Sauvat A, Sica V, Izzo V, Durand S., et al. The oncolytic peptide LTX-315 kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization. Oncotarget 2015; 6: 26599-26614
27. Eike LM, Yang N, Rekdal O, Sveinbjornsson B. The oncolytic peptide LTX-315 induces cell death and DAMP release by mitochondria distortion in human melanoma cells. Oncotarget 2015; 6: 34910-34923
28. Camilio KA, Berge G, Ravuri CS, Rekdal O, Sveinbjornsson B. Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315. Cancer Immunol Immunother 2014; 63: 601-613
29. Camilio KA, Rekdal O, Sveinbjornsson B. LTX-315 (oncopore): a short synthetic anticancer peptide and novel immunotherapeutic agent. Oncoimmunology 2014; 3: e29181
30. Forveille S, Zhou H, Sauvat A, Bezu L, Muller K, Liu P., et al. The oncolytic peptide LTX-315 triggers necrotic cell death. Cell Cycle 2015; 14: 3506-3512
31. Spicer JAA, Brunsvig P, Saunders A, Olsen WM, Nicolaisen B, Rekdal O., et al. Intratumoural treatment with LTX-315, an oncolytic peptide immunotherapy, in patients with advanced metastatic disease induces CD8 effector cells and regression in some injected tumours. Eur Cancer Congr 2015 2015
32. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-1059
33. Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J., et al. Cancer cell-Autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 2014; 20: 1301-1309
34. Hannani D, Vetizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D., et al. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res 2015; 25: 208-224
35. Zhou H, Forveille S, Sauvat A, Yamazaki T, Senovilla L, Ma Y., et al. The oncolytic peptide LTX-315 triggers immunogenic cell death. Cell Death Differ 2015; 7: e2134
36. Ngiow SF, Young A, Jacquelot N, Yamazaki T, Enot D, Zitvogel L., et al. A threshold level of intratumor CD8+ T-cell PD1 expression dictates therapeutic response to Aanti-PD1. Cancer Res 2015; 75: 3800-3811
37. Vacchelli E, Ma Y, Baracco EE, Sistigu A, Enot DP, Pietrocola F., et al. Chemotherapyinduced antitumor immunity requires formyl peptide receptor 1. Science 2015; 350: 972-978
38. Roux S, Apetoh L, Chalmin F, Ladoire S, Mignot G, Puig PE., et al. CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer. J Clin Invest 2008; 118: 3751-3761
39. Klug F, Prakash H, Huber PE, Seibel T, Bender N, Halama N., et al. Low-dose irradiation programs macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 2013; 24: 589-602
40. Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillere R, Hannani D., et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013; 342: 971-976
41. Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA., et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013; 342: 967-970
42. Sivan A, Corrales L, Hubert N,Williams JB, Aquino-Michaels K, Earley ZM., et al. Commensal bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 2015; 350: 1084-1089
43. Vetizou M, Pitt JM, Daillere R, Lepage P, Waldschmitt N, Flament C., et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 2015; 350: 1079-1084
44. Urbaniak C, Cummins J, Brackstone M, Macklaim JM, Gloor GB, Baban CK., et al. Microbiota of human breast tissue. Appl Environ Microbiol 2014; 80: 3007-3014